Orexo’s Q316 results delivered positive momentum in Zubsolv revenues and market share. Exclusive preferred status on Maryland FFS Medicaid from July boosted Zubsolv’s market share in the public segment by 1.4pp. In the coming quarters we expect further US market share gains. Orexo is targeting a disproportionally higher share of new patients embarking on opioid dependence treatment, enabled by continued salesforce optimisation. The impact of the US Department of Health and Human S
04 Nov 2016
Zubsolv gathers momentum
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Zubsolv gathers momentum
Orexo’s Q316 results delivered positive momentum in Zubsolv revenues and market share. Exclusive preferred status on Maryland FFS Medicaid from July boosted Zubsolv’s market share in the public segment by 1.4pp. In the coming quarters we expect further US market share gains. Orexo is targeting a disproportionally higher share of new patients embarking on opioid dependence treatment, enabled by continued salesforce optimisation. The impact of the US Department of Health and Human S